PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 144 filers reported holding PROTAGONIST THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.37 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $942,000 | +21.5% | 39,771 | +75.6% | 0.00% | – |
| Q4 2021 | $775,000 | +114.1% | 22,651 | +10.8% | 0.00% | – |
| Q3 2021 | $362,000 | -88.7% | 20,434 | -71.4% | 0.00% | -100.0% |
| Q2 2021 | $3,204,000 | +207.8% | 71,400 | +77.6% | 0.00% | +100.0% |
| Q1 2021 | $1,041,000 | +6.4% | 40,199 | -17.1% | 0.00% | 0.0% |
| Q4 2020 | $978,000 | +670.1% | 48,502 | +170.5% | 0.00% | – |
| Q1 2020 | $127,000 | -0.8% | 17,931 | -1.5% | 0.00% | – |
| Q4 2019 | $128,000 | -39.3% | 18,199 | +3.7% | 0.00% | – |
| Q3 2019 | $211,000 | +1.0% | 17,555 | +1.9% | 0.00% | – |
| Q2 2019 | $209,000 | -2.8% | 17,233 | +0.6% | 0.00% | – |
| Q1 2019 | $215,000 | +70.6% | 17,127 | -8.3% | 0.00% | – |
| Q4 2018 | $126,000 | -36.7% | 18,680 | -3.6% | 0.00% | – |
| Q3 2018 | $199,000 | +27.6% | 19,382 | -16.3% | 0.00% | – |
| Q2 2018 | $156,000 | – | 23,157 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $19,373,000 | 4.95% |
| Bain Capital Life Sciences Investors, LLC | 2,260,572 | $17,881,000 | 2.10% |
| Finepoint Capital LP | 735,126 | $5,815,000 | 2.01% |
| Altium Capital Management LP | 365,100 | $2,888,000 | 1.16% |
| RTW INVESTMENTS, LP | 4,794,499 | $37,924,000 | 0.98% |
| Amitell Capital Pte Ltd | 50,129 | $397,000 | 0.90% |
| COWEN AND COMPANY, LLC | 1,065,724 | $8,430,000 | 0.81% |
| Tri Locum Partners LP | 155,000 | $1,226,000 | 0.50% |
| BVF INC/IL | 1,106,838 | $8,755,000 | 0.42% |
| HighVista Strategies LLC | 46,459 | $367,000 | 0.22% |